GrayMatters Health

GrayMatters Health develops Prism, an interventional psychiatry software platform that leverages fMRI-informed digital biomarkers and EEG neurofeedback to deliver personalized psychiatric care. The company's core technology uses real-time brain activity monitoring via EEG sensors to help patients self-regulate neural patterns associated with mental health conditions. Prism offers clinically validated protocols for PTSD (utilizing amygdala-based biomarkers) and Major Depressive Disorder (targeting ventral striatum reward-system activity). The platform integrates into clinical workflows, allowing technicians to administer sessions under clinician supervision, optimizing operational efficiency. GrayMatters emphasizes evidence-based design with published clinical studies demonstrating efficacy in symptom reduction and improved patient outcomes. The company provides comprehensive support including onsite installation, staff training, and ongoing technical assistance. Prism represents a bridge between neuroscience research and accessible psychiatric practice, enabling clinicians to augment standard-of-care therapies with objective, brain-derived biomarker data. The technology is designed for clinic deployment with minimal storage footprint and seamless integration into existing treatment protocols.